<code id='CB9D109C53'></code><style id='CB9D109C53'></style>
    • <acronym id='CB9D109C53'></acronym>
      <center id='CB9D109C53'><center id='CB9D109C53'><tfoot id='CB9D109C53'></tfoot></center><abbr id='CB9D109C53'><dir id='CB9D109C53'><tfoot id='CB9D109C53'></tfoot><noframes id='CB9D109C53'>

    • <optgroup id='CB9D109C53'><strike id='CB9D109C53'><sup id='CB9D109C53'></sup></strike><code id='CB9D109C53'></code></optgroup>
        1. <b id='CB9D109C53'><label id='CB9D109C53'><select id='CB9D109C53'><dt id='CB9D109C53'><span id='CB9D109C53'></span></dt></select></label></b><u id='CB9D109C53'></u>
          <i id='CB9D109C53'><strike id='CB9D109C53'><tt id='CB9D109C53'><pre id='CB9D109C53'></pre></tt></strike></i>

          hotspot

          hotspot

          author:fashion    Page View:992
          Mark Lennihan/AP

          Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

          The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

          advertisement

          Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          The haunting brain science of long Covid
          The haunting brain science of long Covid

          AdobeMattFitzgeraldusedtobikeupanddown3,500feetthroughtheSantaAnaMountainsonthree-hourridesjustforfu

          read more
          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more

          New lawsuit accuses health insurer Cigna of denying claims in bulk

          AnewlawsuitaccusesthehealthinsurerCignaofdenyingclaimsinbulk.JuliaRendleman/GettyImagesforEventiveMa